Robert C. Doebele

31.5k citations

250 papers · 10.4k indexed · 5 hit papers · h-index 53

Impact in

Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Oncology top 0.2%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers

Papers in

Pulmonary and Respiratory Medicine 204
- Lung Cancer Treatments and Mutations 196
- Lung Cancer Diagnosis and Treatment 18
Oncology 161
- Lung Cancer Research Studies 65
- Colorectal Cancer Treatments and Studies 48
- HER2/EGFR in Cancer Research 23

Co-authors: D. Ross Camidge Dara L. Aisner Marileila Varella‐Garcia Anh T. Le Andrew Weickhardt Aria Vaishnavi Kurtis D. Davies Anh‐Tuan Le
Journals: Journal of Clinical Oncology (49 papers)Journal of Thoracic Oncology (36 papers)Annals of Oncology (34 papers)Cancer Research (20 papers)Clinical Cancer Research (9 papers)
Partner nations: United States Italy South Korea

In The Last Decade

Robert C. Doebele

243 papers receiving 10.2k citations

Hit Papers

5 papers align trajectories log scale

Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC 2019 · 356 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2019 Nature Reviews Clinical Oncology
2015 Cancer Discovery
2014 Cancer Discovery
2012 Journal of Thoracic Oncology
2012 Clinical Cancer Research

Peers

Countries citing papers authored by Robert C. Doebele

Since Specialization

Citations

This map shows the geographic impact of Robert C. Doebele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert C. Doebele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert C. Doebele more than expected).

Fields of papers citing papers by Robert C. Doebele

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert C. Doebele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert C. Doebele. The network helps show where Robert C. Doebele may publish in the future.

Co-authors

The 25 scholars most cited alongside Robert C. Doebele, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Robert C. Doebele Line = papers co-authored together Robert C. Doebele links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance Nature Communications ·王宏巍, L. E. Roth, Ai Liani Anggita, Juan Guan, Anh‐Tuan Le, Robert C. Doebele, Bo Huang, D. Monteiro, J. Zhang, Trever G. Bivona, Lukasz J. Bugaj	2024	3
2	Intrinsic resistance to ROS1 inhibition in a patient with CD74‐ROS1 mediated by AXL overexpression Thoracic Cancer ·Li-quan, J Mc Cook Martínez, Leila Baradaran Jamili, Anh T. Le, Anastasios Dimou, Robert C. Doebele	2023	2
3	A functional sgRNA-CRISPR screening method for generating murine RET and NTRK1 rearranged oncogenes Biology Open ·Laura Schubert, Anh‐Tuan Le, Trista K. Hinz, Andre Navarro, Абдулло Азаматов, Raphael A. Nemenoff, Lynn E. Heasley, Robert C. Doebele	2023	2
4	ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression Proceedings of the National Academy of Sciences ·人事院任用局企画課, Wei‐Yun Lai, Ramadha Awaliati, Ricardo Andrés Ramírez Castañeda, Ganesh Umapathy, Hongryul Lee, Bengt Bergman, Ajat Sudrajat, Fredrik B. Thorén, Anh T. Le, Robert C. Doebele, Jimmy Van den Eynden, Ruth H. Palmer, Bengt Hallberg	2023	15
5	Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma JCI Insight ·Simon Derek Miller, 光正中南, Kara M. Soroko, D D K Rolston, Laura Ramos Bravo, Prafulla C. Gokhale, Vijaya G. Tirunagaru, Robert C. Doebele, James A. DeCaprio	2022	11
6	Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data inROS1+ NSCLC Journal of Comparative Effectiveness Research ·Robert C. Doebele, نورالدين زرادي, Huong Trinh, 真美三木, Reynaldo Martina, Todd Riehl, Matthew Krebs, Neal J. Meropol, William B. Wong, Gracy Crane	2021	14
7	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or MetastaticROS1Fusion–Positive Non–Small-Cell Lung Cancer Journal of Clinical Oncology ·Rafał Dziadziuszko, Matthew Krebs, Filippo de Braud, Salvatore Siena, Alexander Drilon, Robert C. Doebele, Manish Patel, Byoung Chul Cho, Stephen V. Liu, Myung‐Ju Ahn, Chao‐Hua Chiu, Anna F. Farago, Chia‐Chi Lin, Christos S. Karapetis, Yu Li, Bann‐Mo Day, David Chen, Timothy R. Wilson, Fabrice Barlési	2021	111
8	Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms Journal for ImmunoTherapy of Cancer ·Alexander Neuwelt, Abigail K. Kimball, Amber M. Johnson, Ana Paula Arnholdt, Bonnie Bullock, Rachael E. Kaspar, Emily K. Kleczko, Jeff Kwak, Meng‐Han Wu, Lynn E. Heasley, Robert C. Doebele, Howard Li, Raphael A. Nemenoff, Eric T. Clambey	2020	37
9	O-3 Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis of three clinical trials (STARTRK-2, STARTRK-1 and ALKA-372-001) Annals of Oncology ·Manish R. Patel, Salvatore Siena, George D. Demetri, Robert C. Doebele, Younbyoung Chae, Paul Conkling, Ignacio Garrido‐Laguna, Federico Longo, Christian Rolfo, Darren Sigal, Alexander Drilon, 佐土海伊橋, Kōichi Goto, Lyudmila Bazhenova, Sara Lonardi, Fortunato Ciardiello, Xiaoxiao Huang, Stuart Osborne, Gabriela Villanueva Caceres, Filippo de Braud	2020	13
10	Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations Clinical Cancer Research ·Thereasa A. Rich, Karen L. Reckamp, Young Kwang Chae, Robert C. Doebele, Wade T. Iams, Michael S. Oh, Victoria M. Raymond, Richard B. Lanman, Jonathan W. Riess, Thomas E. Stinchcombe, Vivek Subbiah, David R. Trevarthen, Stephen R. Fairclough, Jennifer Yen, Oliver Gautschi	2019	68
11	Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non–small Cell Lung Cancer Clinical Cancer Research ·Caroline E. McCoach, Anh T. Le, Katherine Gowan, Kenneth A. Jones, Laura Schubert, Andrea E. Doak, Adriana Estrada‐Bernal, Antônio Lucineudo de Oliveira Ferreira, Daniel T. Merrick, Paul A. Bunn, F. Green, Rafał Dziadziuszko, Marileila Varella‐Garcia, Dara L. Aisner, D. Ross Camidge, Robert C. Doebele	2018	179
12	Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer Clinical Cancer Research ·Caroline E. McCoach, Collin M. Blakely, Kimberly C. Banks, Benjamin Levy, 直樹曽我部, Victoria M. Raymond, Anh T. Le, Christine E. Lee, Joseph A. Diaz, Saiama N. Waqar, W. Thomas Purcell, Dara L. Aisner, Antônio Lucineudo de Oliveira Ferreira, Richard B. Lanman, Alice T. Shaw, Robert C. Doebele	2018	114
13	Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins Cancer Research ·Dana S. Neel, Shota Hamano, Victor Olivas, Manasi K. Mayekar, Golzar Hemmati, Nilanjana Chatterjee, Collin M. Blakely, Caroline E. McCoach, Julia Rotow, Anh T. Le, Niki Karachaliou, Rafael Rosell, Jonathan W. Riess, Robert J. Nichols, Robert C. Doebele, Trever G. Bivona	2018	63
14	Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling Molecular Cancer Therapeutics ·Абдулло Азаматов, Anh T. Le, Minjae Yoo, Laura Schubert, Toru Nakamura, Andrea E. Doak, Marileila Varella‐Garcia, Aik Choon Tan, Robert C. Doebele	2017	63
15	EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases Cancer Research ·Aria Vaishnavi, Laura Schubert, Uwe Rix, Lindsay A. Marek, Anh T. Le, Stephen B. Keysar, Magdalena J. Glogowska, Matthew A. Smith, Severine Kako, Natália J. Sumi, Kurtis D. Davies, Kathryn E. Ware, Marileila Varella‐Garcia, Eric B. Haura, Antonio Jimeno, Lynn E. Heasley, Dara L. Aisner, Robert C. Doebele	2017	61
16	An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101 Cancer Discovery ·Robert C. Doebele, Lara E. Davis, Aria Vaishnavi, Anh T. Le, Adriana Estrada‐Bernal, Stephen B. Keysar, Antonio Jimeno, Marileila Varella‐Garcia, Dara L. Aisner, Yali Li, Philip J. Stephens, Deborah Morosini, Brian B. Tuch, Michele Fernandes, Nisha Nanda, Jennifer A. Low Hit paper breakdown →	2015	302
17	Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer Cancer Discovery ·Jim Sang, Jaime Acquaviva, Julie C. Friedland, Donald L. Smith, Manuel Sequeira, Chaohua Zhang, Qin Jiang, Liquan Xue, Christine M. Lovly, Laura Aillaud, Alice T. Shaw, Robert C. Doebele, Suqin He, Richard C. Bates, D. Ross Camidge, Stephan W. Morris, Iman El‐Hariry, David A. Proia	2013	174
18	Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer Clinical Cancer Research ·Robert C. Doebele, Amanda Pilling, Dara L. Aisner, Tatiana G. Kutateladze, Anh T. Le, Andrew Weickhardt, Kimi Kondo, Derek J. Linderman, Lynn E. Heasley, Wilbur A. Franklin, Marileila Varella‐Garcia, D. Ross Camidge Hit paper breakdown →	2012	820
19	Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer Clinical Cancer Research ·Kurtis D. Davies, Anh T. Le, Mariana F. Theodoro, Margaret C. Skokan, Dara L. Aisner, Eamon M. Berge, Luigi Terracciano, Federico Cappuzzo, Matteo Incarbone, Massimo Roncalli, Marco Alloisio, Armando Santoro, D. Ross Camidge, Marileila Varella‐Garcia, Robert C. Doebele	2012	330
20	Point Mutations in or Near the Antigen-Binding Groove of HLA-DR3 Implicate Class II-Associated Invariant Chain Peptide Affinity as a Constraint on MHC Class II Polymorphism The Journal of Immunology ·Robert C. Doebele, Achal Pashine, Wendy Liu, Dennis M. Zaller, Michael P. Belmares, Robert Busch, Elizabeth Mellins	2003	25

About Robert C. Doebele

Robert C. Doebele is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Pathology and Forensic Medicine and Molecular Biology, having authored 250 papers that have together received 10.4k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (196 papers), Cancer Genomics and Diagnostics (65 papers), Lung Cancer Research Studies (65 papers), Colorectal Cancer Treatments and Studies (48 papers), HER2/EGFR in Cancer Research (23 papers), PI3K/AKT/mTOR signaling in cancer (19 papers), Cancer therapeutics and mechanisms (19 papers) and Lung Cancer Diagnosis and Treatment (18 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (7.3k citations), Oncology (6.1k citations), Cancer Research (2.3k citations), Molecular Biology (4.0k citations) and Pathology and Forensic Medicine (993 citations). Robert C. Doebele has collaborated with scholars based in United States, Italy and South Korea. Frequent co-authors include D. Ross Camidge, Dara L. Aisner, Marileila Varella‐Garcia, Anh T. Le, Andrew Weickhardt, Aria Vaishnavi, Kurtis D. Davies, Anh‐Tuan Le, Wilbur A. Franklin and Paul A. Bunn. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Annals of Oncology, Cancer Research and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact